Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ravikiran Panakanti"'
Publikováno v:
Journal of Applied Pharmaceutical Science. :26-35
Publikováno v:
International Journal of Pharmaceutical Investigation. 12:46-50
Autor:
Corinne Renault, Ibraheem M. Rajab, Magdalena Bujok, Daniel A. Gbadero, Sinni Moozhayil, Lawrence O. Farayola, Moji Christianah Adeyeye, Brandon Swinford, Nikolaos Olalere, Ravikiran Panakanti
Background: An undocumented complementary and alternative medicine (CAM)- Faradin® - was screened for its phytochemicals, anti-sickling effect using a clinical protocol, and toxicity. Faradin is a polyherbal made up of Zanthoxylum zanthoxyloides, Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe688538ef439cea973e85a3cb1dc32
https://zenodo.org/record/822658
https://zenodo.org/record/822658
Autor:
Ravikiran Panakanti
Publikováno v:
Open Access Journal of Pharmaceutical Research. 1
Autor:
James D. Eason, Ningning Yang, Ram I. Mahato, Akshay Pratap, Saurabh Singh, Vaibhav Mundra, Ravikiran Panakanti
Publikováno v:
Journal of Drug Targeting. 20:770-782
Hedgehog (Hh) signaling is involved in the pathogenesis of liver fibrosis. It has been previously shown that Hh-inhibitor cyclopamine (CYA) can reduce liver fibrosis in rats. However, CYA is not stable in vivo, which limits its clinical application.
Autor:
Ajit S. Narang, Ravikiran Panakanti
Publikováno v:
Pharmaceutical Research. 29:2639-2659
Excipients are generally pharmacologically inert, but can interact with drugs in the dosage form and the physiological factors at the site of absorption to affect the bioavailability of a drug product. A general mechanistic understanding of the basis
Publikováno v:
Biochemical Pharmacology. 80:1718-1726
Liver fibrosis is a consequence of chronic liver disorders which lead to the accumulation of extracellular matrix (ECM). Particularly, there is an increased accumulation of collagen in the fibrotic liver. We have therefore used a triplex forming olig
Autor:
Ravikiran Panakanti, Ram I. Mahato
Publikováno v:
Molecular Pharmaceutics. 6:274-284
Ex vivo gene transfer can improve the outcome of islet transplantation for treating type I diabetes. Earlier we have shown coexpression of human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after tr
Autor:
Ram I. Mahato, Ravikiran Panakanti
Publikováno v:
Pharmaceutical Research. 26:587-596
Ex vivo gene therapy can improve the outcome of islet transplantation for treating type I diabetes. Hepatocyte growth factor (HGF) increases beta-cell proliferation and promotes revascularization of islets, while interleukin-1 receptor antagonist (hI